Phase 1 × Lymphoma, Extranodal NK-T-Cell × Clear all
NCT05377827 2025-04-29

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Washington University School of Medicine

Phase 1 Active not recruiting
6 enrolled
NCT02168140 2024-02-13

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Wake Forest University Health Sciences

Phase 1 Completed
16 enrolled
NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Stanford University

Phase 1 Terminated
3 enrolled 5 charts
NCT01523223 2023-11-22

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Stanford University

Phase 1 Completed
16 enrolled
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Swiss Cancer Institute

Phase 1 Completed
18 enrolled
NCT01129193 2018-06-04

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
44 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT01748721 2016-01-08

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Morphotek

Phase 1 Completed
27 enrolled
NCT01658319 2015-08-13

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
20 enrolled
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT00800150 2015-06-08

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

City of Hope Medical Center

Phase 1 Terminated
6 enrolled
NCT00352443 2015-03-06

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

SWOG Cancer Research Network

Phase 1 Completed
66 enrolled
NCT00343798 2015-02-11

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase 1 Completed
23 enrolled
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00458744 2014-08-08

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Children's Oncology Group

Phase 1 Withdrawn
NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
NCT00521261 2014-03-05

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
NCT00499811 2014-02-24

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

National Cancer Institute (NCI)

Phase 1 Completed
57 enrolled
NCT01273090 2014-01-30

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Children's Oncology Group

Phase 1 Completed
34 enrolled
NCT00769288 2014-01-07

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
NCT01129180 2013-12-03

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
8 enrolled
NCT00996359 2013-09-17

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Rutgers, The State University of New Jersey

Phase 1 Terminated
4 enrolled
NCT00562380 2013-07-18

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
64 enrolled
NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
NCT00659568 2013-05-30

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
28 enrolled
NCT00354185 2013-05-16

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00962507 2013-02-15

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
11 enrolled
NCT00891072 2013-01-10

Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled